<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901014</url>
  </required_header>
  <id_info>
    <org_study_id>M-0419</org_study_id>
    <nct_id>NCT03901014</nct_id>
  </id_info>
  <brief_title>Investigating the Production of Lipoproteins and Acetyl-CoA During a Ketogenic Diet</brief_title>
  <acronym>PLAK</acronym>
  <official_title>Investigating the Production of Lipoproteins and Acetyl-CoA During a Ketogenic Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Touro University, California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Touro University, California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how the reduction in dietary carbohydrates in a
      very-low carbohydrate ketogenic diet impacts the synthesis of cholesterol, fatty acid, and
      ketones, and the turnover rate of VLDL and chylomicron particles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will consume a standard American diet for one week followed by a very-low
      carbohydrate ketogenic diet (VLCKD, &lt;50 grams carbohydrate/day) for two weeks. Participants
      will undergo an oral stable isotope tracer study during each diet to measure de novo
      synthesis of fatty acid, cholesterol, ketone bodies, and for measurement of apolipoprotein B
      and triglyceride kinetics.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">April 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The nature of the diet does not allow for masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total cholesterol</measure>
    <time_frame>Day 3-7 to Day 17-21</time_frame>
    <description>Change in serum total cholesterol between Day 3-7 (average value) to Day 17-21 (average value)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in low density lipoprotein (LDL) cholesterol</measure>
    <time_frame>Day 3-7 to Day 17-21</time_frame>
    <description>Change in serum LDL cholesterol between Day 3-7 (average value) to Day 17-21 (average value)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in high density lipoprotein (HDL) cholesterol</measure>
    <time_frame>Day 3-7 to Day 17-21</time_frame>
    <description>Change in serum HDL cholesterol between Day 3-7 (average value) to Day 17-21 (average value)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in apolipoprotein B (apoB) kinetics</measure>
    <time_frame>Day 3-7 to Day 17-21</time_frame>
    <description>Change in apoB turnover rates in LDL and very low density lipoprotein plasma fractions as measured using 2H2 leucine incorporation into apoB and mathematical modeling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fractional hepatic de novo lipogenesis</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Measured by the detection of incorporated 1-13C sodium acetate into palmitate in triglyceride rich lipoproteins (TRL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fractional cholesterol synthesis</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Measured by the detection of incorporated 1-13C sodium acetate into cholesterol in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ketone body synthesis</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Measured by the detection of incorporated 1-13C sodium acetate into ketone bodies in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TRL-triglyceride kinetics</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Change in TRL- triglyceride assembly rates as measured using 2-13C glycerol and mathematical modeling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride lipolysis</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Measured by the dilution of administered 2-13C glycerol in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum glucose concentration</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Change in fasting and postprandial serum glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum free fatty acid concentration</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Change in fasting and postprandial serum free fatty acid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum insulin concentration</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Change in fasting and postprandial serum insulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum ketone body concentration</measure>
    <time_frame>Day 3 to Day 17</time_frame>
    <description>Change in fasting and postprandial ketone body levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cholesterol Metabolism</condition>
  <condition>Ketone Metabolism</condition>
  <arm_group>
    <arm_group_label>Baseline diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 week baseline diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very low carbohydrate diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 week very low carbohydrate ketogenic diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard American diet</intervention_name>
    <description>Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.</description>
    <arm_group_label>Baseline diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Very low carbohydrate diet</intervention_name>
    <description>Ketogenic diet with &lt;50g carbohydrate, 60-75% energy from fat, and 20% from protein</description>
    <arm_group_label>Very low carbohydrate diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  18-50 years old

        Exclusion Criteria:

          -  Use of nicotine products

          -  Has dietary restrictions

          -  Lactose intolerance

          -  History of GI disorders, diabetes, liver, kidney, or thyroid disorders

          -  Taking hypolipidemic, anti-diabetic, anti-hypertensive, or anti-depression medication

          -  Screening plasma triglyceride &lt; 50mg/dl or &gt;500mg/dl

          -  Screening glucose &gt; 125mg/dl

          -  Screening total and LDL-Cholesterol over 95th %tile for age and sex

          -  BP &gt; 160/95 mmHg

          -  Weight loss/gain &gt; 5% in the previous 3 months (self-reported)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace M Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Touro University, California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Touro University California</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94592</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ketogenic diet</keyword>
  <keyword>LDL cholesterol</keyword>
  <keyword>carbohydrate</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

